[
  {
    "ts": null,
    "headline": "AI Bubble or Sustainable Growth? Here Are 2 Healthcare Companies Harnessing AI for the Long Term.",
    "summary": "Artificial intelligence may be all the rage in the technology sector, but it's also having a huge impact on healthcare.",
    "url": "https://finnhub.io/api/news?id=a4ab0ce55c9fa57739bd1a7174b888d2534b2fdd06d55615823a44b039d30a87",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769212200,
      "headline": "AI Bubble or Sustainable Growth? Here Are 2 Healthcare Companies Harnessing AI for the Long Term.",
      "id": 138229884,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Artificial intelligence may be all the rage in the technology sector, but it's also having a huge impact on healthcare.",
      "url": "https://finnhub.io/api/news?id=a4ab0ce55c9fa57739bd1a7174b888d2534b2fdd06d55615823a44b039d30a87"
    }
  },
  {
    "ts": null,
    "headline": "Reassessing Bristol Myers Squibb (BMY) After Mixed Returns And Product Pipeline Developments",
    "summary": "If you are wondering whether Bristol-Myers Squibb is offering good value at around US$54.94 per share, you are not alone. Many investors are asking the same question right now. The stock has had mixed returns, with a 3% decline over the last 7 days, a 1.2% gain over the last 30 days, a 2.8% gain year to date, and a 2.4% decline over the last year. The 3-year and 5-year returns sit at a 13.7% decline and a 7.6% gain respectively. Recent headlines around Bristol-Myers Squibb have focused on...",
    "url": "https://finnhub.io/api/news?id=186eba1d518b58365d949d2676cb39cb3b7899e707020e501fd8e4ce744f453e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769198805,
      "headline": "Reassessing Bristol Myers Squibb (BMY) After Mixed Returns And Product Pipeline Developments",
      "id": 138229409,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "If you are wondering whether Bristol-Myers Squibb is offering good value at around US$54.94 per share, you are not alone. Many investors are asking the same question right now. The stock has had mixed returns, with a 3% decline over the last 7 days, a 1.2% gain over the last 30 days, a 2.8% gain year to date, and a 2.4% decline over the last year. The 3-year and 5-year returns sit at a 13.7% decline and a 7.6% gain respectively. Recent headlines around Bristol-Myers Squibb have focused on...",
      "url": "https://finnhub.io/api/news?id=186eba1d518b58365d949d2676cb39cb3b7899e707020e501fd8e4ce744f453e"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of Jan 25",
    "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read the full list here.",
    "url": "https://finnhub.io/api/news?id=51cad26e98a55cff634e728377ee94ee04cf1e5384eb442f6922079bdc07e397",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769191913,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of Jan 25",
      "id": 138229764,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read the full list here.",
      "url": "https://finnhub.io/api/news?id=51cad26e98a55cff634e728377ee94ee04cf1e5384eb442f6922079bdc07e397"
    }
  },
  {
    "ts": null,
    "headline": "Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?",
    "summary": "Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.",
    "url": "https://finnhub.io/api/news?id=921ed78dba5a3de16564bf3d9a0f6185fc07cb3cdabc7269749e54bbca782115",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769191500,
      "headline": "Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?",
      "id": 138228445,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.",
      "url": "https://finnhub.io/api/news?id=921ed78dba5a3de16564bf3d9a0f6185fc07cb3cdabc7269749e54bbca782115"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion",
    "summary": "BMY's collaboration with Janux Therapeutics positions it to enter the solid tumor market. Read the latest analysis on the stock here.",
    "url": "https://finnhub.io/api/news?id=c5cb0fe2ef5441f695f490a111b43342cb06a59fa7e90d0f43e2ca5f30753f8e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769183564,
      "headline": "Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion",
      "id": 138229056,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254082934/image_2254082934.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "BMY's collaboration with Janux Therapeutics positions it to enter the solid tumor market. Read the latest analysis on the stock here.",
      "url": "https://finnhub.io/api/news?id=c5cb0fe2ef5441f695f490a111b43342cb06a59fa7e90d0f43e2ca5f30753f8e"
    }
  },
  {
    "ts": null,
    "headline": "A Look At Bristol Myers Squibb (BMY) Valuation After New Microsoft AI Pact And Camzyos Trial Results",
    "summary": "Bristol Myers Squibb (BMY) is back in focus after two key updates: a new AI lung cancer screening agreement with Microsoft, and positive Phase 3 data for Camzyos in adolescents with obstructive hypertrophic cardiomyopathy. See our latest analysis for Bristol-Myers Squibb. Those AI and cardiology updates come after a busy start to 2026, including oncology focused deals like the new Janux Therapeutics agreement. They follow a 90 day share price return of 25.35% against a weaker 1 year total...",
    "url": "https://finnhub.io/api/news?id=cf485bfeb86866e131e7444069e69f6fc146beed2f784bc853309e6245a5e63f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769181082,
      "headline": "A Look At Bristol Myers Squibb (BMY) Valuation After New Microsoft AI Pact And Camzyos Trial Results",
      "id": 138225575,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb (BMY) is back in focus after two key updates: a new AI lung cancer screening agreement with Microsoft, and positive Phase 3 data for Camzyos in adolescents with obstructive hypertrophic cardiomyopathy. See our latest analysis for Bristol-Myers Squibb. Those AI and cardiology updates come after a busy start to 2026, including oncology focused deals like the new Janux Therapeutics agreement. They follow a 90 day share price return of 25.35% against a weaker 1 year total...",
      "url": "https://finnhub.io/api/news?id=cf485bfeb86866e131e7444069e69f6fc146beed2f784bc853309e6245a5e63f"
    }
  },
  {
    "ts": null,
    "headline": "JANX Enters Global Oncology Collaboration With BMY, Stock Rises",
    "summary": "Janux Therapeutics struck a global licensing deal for its tumor-activated platforms, sending shares higher and expanding its reach in solid tumors.",
    "url": "https://finnhub.io/api/news?id=b75d7e2fb0d5805d0c863a4bbfa8b099c51cffca1b1ff6ce60c39e6419ec31f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769170680,
      "headline": "JANX Enters Global Oncology Collaboration With BMY, Stock Rises",
      "id": 138224856,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Janux Therapeutics struck a global licensing deal for its tumor-activated platforms, sending shares higher and expanding its reach in solid tumors.",
      "url": "https://finnhub.io/api/news?id=b75d7e2fb0d5805d0c863a4bbfa8b099c51cffca1b1ff6ce60c39e6419ec31f8"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Dodged a Patent Disaster, and Shares Gained 460%. Merck and Bristol Myers Are Next.",
    "summary": "AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers Squibb face similar patent cliffs.",
    "url": "https://finnhub.io/api/news?id=7f99158813c633d0e2153683ce19bb53378d72df1f24fbd52fc9338223c80772",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769149800,
      "headline": "AbbVie Dodged a Patent Disaster, and Shares Gained 460%. Merck and Bristol Myers Are Next.",
      "id": 138222072,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers Squibb face similar patent cliffs.",
      "url": "https://finnhub.io/api/news?id=7f99158813c633d0e2153683ce19bb53378d72df1f24fbd52fc9338223c80772"
    }
  }
]